Aandeel ALLR ALLARITY THERAPEUTICS, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Allarity Therapeutics, Inc.

Aandelen

ALLR

US0167444019

Beurs gesloten - Nasdaq
Andere beurzen
 22:00:00 25-06-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
0,208 USD -34,80% Intraday-grafiek van Allarity Therapeutics, Inc. -52,87% -98,11%
25/06 De dubbele PARP/Tankyrase-remmer van Allarity Therapeutics, Inc., stenoparib, blijft verlengd klinisch voordeel vertonen bij gevorderde eierstokkanker CI
24/05 Allarity Therapeutics, Inc. Beëindigt haar Fase 2 Klinische Studie CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
Allarity Therapeutics, Inc.' Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
Allarity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
Allarity Therapeutics Says Stockholders' Equity 'Significantly' Exceeds Nasdaq's $2.5 Million Minimum Rule
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
Wall Street Set to Open Higher Thursday After Fed Holds Rate Steady, Jobless Claims Lower Than Expected
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
Allarity Therapeutics, Inc. Announces Early Discontinuation of Its Phase 2 Clinical Trial of Stenoparib
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
Top Premarket Gainers
Top Premarket Gainers
Allarity Therapeutics to Implement 1-for-20 Reverse Stock Split
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers ALLR
  4. Nieuws Allarity Therapeutics, Inc.
  5. Andere talen